Efficacy testing of recombinant human immunodeficiency virus (HIV) gp160 as a therapeutic vaccine in early-stage HIV-1-infected volunteers

Journal of Infectious Diseases

Volumn 181, Issue 3, 2000, Pages 881-889

  Birx, Deborah L ^a   Loomis Price, Lawrence D ^b   Aronson, Naomi ^d   Brundage, John ^a   Davis, Charles ^i,j,k   Deyton, Lawrence ^c   Garner, Robin ^b   Gordin, Fred ^g   Henry, David ^l   Holloway, William ^m   Kerkering, Thomas ^c   Luskin Hawk, Roberta ^o   McNeil, John ^a   Michael, Nelson ^a   Pierce, Phillip Foster ^h   Poretz, Donald ⁿ   Ratto Kim, Silvia ^b   Renzullo, Phil ^b   Ruiz, Nancy ^d   Sitz, Karl ^a   Smith, Gale ^p   Tacket, Carol ^e   Thompson, Melanie ^t   Tramont, Edmond ^f   Yangco, Bienvenido ^q   Yarrish, Robert ^r   Redfield, Robert R ^a,s   more..

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d WALTER REED ARMY MEDICAL CENTER   (United States)

^e Center for Vaccine Development   (United States)

^f UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^g VETERANS AFFAIRS MEDICAL CENTER   (United States)

^h GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

ⁱ WILFORD HALL MEDICAL CENTER   (United States)

^j WILLIAM BEAUMONT ARMY MEDICAL CENTER   (United States)

^k CARL R DARNALL ARMY MEDICAL CENTER   (United States)

^l GRADUATE HOSPITAL   (United States)

^m Delaware CPCRA   (United States)

ⁿ Infectious Diseases Physicians Inc   (United States)

^o AIDS Research Alliance   (United States)

^p MicroGeneSys Inc   (United States)

^q INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

^r ST VINCENT S HOSPITAL   (United States)

^s INSTITUTE OF HUMAN VIROLOGY   (United States)

^t Institute for Human Virology ^*

more..

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; RECOMBINANT GLYCOPROTEIN GP 120; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; ERYTHEMA; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VACCINATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; ADULT; AIDS VACCINES; CD4 LYMPHOCYTE COUNT; DOUBLE-BLIND METHOD; FEMALE; HIV ENVELOPE PROTEIN GP160; HIV-1; HUMANS; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; RNA, VIRAL; VACCINES, SYNTHETIC;

EID: 0034071418     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315308     Document Type: Article

References (51)

1. 1. 1. Zagury D, Gagne I, Reveil B, et al. Repairing the T-cell defect in AIDS. Lancet 1985; 2:449.
2. 2. Salk J. Prospects for the control of AIDS by immunizing seropositive individuals. Nature 1987; 327:473-6.
3. 3. Zagury D, Leonard R, Fouchard M, et al. immunization against AIDS in humans. Nature 1987; 326:249-50.
4. 4. Redfield RR, Birx DL, Ketter N, et al. A phase 1 evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. Military Medical Consortium for Applied Retroviral Research. N Engl J Med 1991; 324: 1677-84.
5. 5. Auzias-Turenne. Syphilization. The collected works of Dr. Auzias-Turenne. Compiled through the efforts of his friends. Paris: Librairie Germer Baelliere, 1878.
6. 6. Koch R. The current state of the struggle against tuberculosis. In: Nobel lectures, physiology of medicine. New York: Elsevier, 1962:169-78.
7. 7. Burke DS. Joseph-Alexandre Auzias-Turenne, Louis Pasteur, and early concepts of virulence, attenuation, and vaccination. Perspect Biol Med 1996; 39:171-86.
8. 8. Stanberry LR, Bernstein DI, Burke RL, Pachl C, Myers MG. Vaccination with recombinant herpes simplex virus glycoproteins: protection against initial and recurrent genital herpes. J Infect Dis 1987; 155:914-20.
9. 9. Stanberry LR. Evaluation of herpes simplex virus vaccines in animals: the guinea pig vaginal model. Rev Infect Dis 1991; 13(Suppl 11):S920-3.
10. 10. Altmeyer P, Wehrenberg O, Holzmann H, et al. Treatment of recurrent herpes labialis using a herpes simplex type-I subunit vaccine. A prospective randomized double-blind multicenter study. Hautarzt 1991; 42:759-63.
11. 11. Strauss SE, Savarese B, Tigges M, et al. Induction and enhancement of immune responses to herpes simplex virus type 2 in humans by use of a recombinant glycoprotein D vaccine. J Infect Dis 1993; 167:1045-52.
12. 12. Gurski KJ, Steller MA. Progress and prospects in vaccine therapy for gynecologic cancers. Oncology 1997; 11:1727-34,1739.
13. 13. Slovin SF, Kelly WK, Scher HI. Immunological approaches for the treatment of prostate cancer. Semin Urol Oncol 1998; 16:53-9.
14. 14. Jones VE, Mitchell MS. Therapeutic vaccines for melanoma: progress and problems. Trends Biotechnol 1996; 14:349-55.
15. 15. Baevsky RH, Bartfield JM. Human rabies: a review. Am J Emerg Med 1993; 11:279-86.
16. 16. Shearer GM, Bernstein DC, Tung KS, et al. A model for the selective loss of major histocompatibility complex self-restricted T cell immune responses during the development of acquired immune deficiency syndrome (AIDS). J Immunol 1986; 137:2514-21.
17. 17. Weinhold KJ, Lyerly HK, Matthews TJ, et al. Cellular anti-GP120 cytolytic reactivities in HIV-1 seropositive individuals. Lancet 1988; 1:902-5.
18. 18. Moss RB, Ferre F, Trauger R, et al. Inactivated HIV-1 Immunogen: impact on markers of disease progression. J Acquir Immune Defic Syndr 1994; 7(Suppl 1):S21-7.
19. 19. Trauger RJ, Ferre F, Daigle AE, Effect of immunization with inactivated gp120-depleted human immunodeficiency virus type 1 (HIV-1) immunogen on HIV-1 immunity, viral DNA, and percentage of CD4 cells. J Infect Dis 1994; 169:1256-64.
20. 20. Kelleher AD, Roggensack M, Jaramillo AB, et al. Safety and immunogenicity of a candidate therapeutic vaccine, p24 virus-like particle, combined with zidovudine, in asymptomatic subjects. AIDS 1998; 12:175-82.
21. 21. Berman PW, Gregory TJ, Riddle L, et al. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature 1990; 345:622-5.
22. 22. Keefer MC, Bonnez W, Roberts NJ Jr, Dolin R, Reichman RC. Human immunodeficiency virus (HIV-1) gp160-specific lymphocyte proliferative responses of mononuclear leukocytes from HIV-1 recombinant gp160 vaccine recipients. J Infect Dis 1991; 163:448-53.
23. 23. Clerici M, Tacket CO, Via CS, et al. Immunization with subunit human immunodeficiency virus vaccine generates stronger T helper cell immunity than natural infection. Eur J Immunol 1991; 21:1345-9.
24. 24. Kahn JO, Birx DL. Vaccines directed against HIV: preventive and therapeutic strategies. AIDS Clin Rev 1993-94; 213-38.
25. 25. Schwartz DH, Gorse G, Clements ML, et al. Induction of HIV-1-neutralising and syncytium-inhibiting antibodies in uninfected recipients of HIV-1 IIIB rgp120 subunit vaccine. Lancet 1993; 342:69-73.
26. 26. Belshe RB, Clements ML, Dolin R, et al. Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection. J Infect Dis 1993; 168: 1387-95.
27. 27. Belshe RB, Graham BS, Keefer MC, et al. Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. JAMA 1994; 272:475-80.
28. 28. Lundholm P, Wahren M, Sandstrom E, Volvovitz F, Wahren B. Autoreactivity in HIV-infected individuals does not increase during vaccination with envelope rgp160. Immunol Lett 1994; 41:147-53.
29. 29. Wahren B, Bratt G, Persson C, et al. Improved cell-mediated immune responses in HIV-1-infected asymptomatic individuals after immunization with envelope glycoprotein gp160. J Acquir Immune Defic Syndr 1994; 7:220-9.
30. 30. Graham BS, Reefer MC, McElrath MJ, et al. Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. Ann Intern Med 1996; 125: 270-9.
31. 31. Eron JJ Jr, Ashby MA, Giordano MF, et al. Randomised trial of MNrgp120 HIV-1 vaccine in symptomless HIV-1 infection. Lancet 1996; 348:1547-51.
32. 32. Tsoukas CM, Raboud J, Bernard NF, et al. Active immunization of patients with HIV infection: a study of the effect of VaxSyn, a recombinant HIV envelope subunit vaccine, on progression of immunodeficiency. AIDS Res Hum Retroviruses 1998; 14:483-90.
33. 33. Sandstrom E, Wahren B, Nordic Vac-04 Study Group. Therapeutic immunisation with recornbinant gp160 in HIV-1 infection: a randomised double-blind placebo-controlled trial. Lancet 1999; 353:1735-42.
34. 34. Pontesilli O, Guerra EC, Ammassari A, et al. Phase II controlled trial of post-exposure immunization with recombinant gp160 versus antiretroviral therapy in asymptomatic HIV-1-infected adults. AIDS 1998; 12:473-80.
35. 35. Redfield RR, Wright DC, Tramont EC. The Walter Reed staging classification for HTLV-III/LAV infection. N Engl J Med 1986; 314:131-2.
36. 36. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189-98.
37. 37. Rubinstein LV, Gail MH, Santner TJ. Planning the duration of a comparative clinical trial with loss to follow-up and a period of continued observation. J Chronic Dis 1981; 34:469-79.
38. 38. Birx DL, Brundage J, Larson K, et al. The prognostic utility of delayed-type hypersensitivity skin testing in the evaluation of HIV-infected patients. J Acquir Immune Defic Syndr 1993; 6:1248-57.
39. 39. Birx DL, Redfield RR. Immunotherapeutic strategies in the treatment of HIV infection and AIDS. Curr Opin Immunol 1993; 5:600-7.
40. + T cell subset phenotyping independently predict survival time in patients infected with human immunodeficiency virus. J Infect Dis 1995; 172:79-87.
41. 41. Rodriguez RJ, Dayhoff DE, Chang G, et al. Comparison of serum and plasma viral RNA measurements in primary and chronic human immunodeficiency virus type I infection. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 15:49-53.
42. 42. Loomis LD, Deal CD, Kersey KS, Burke DS, Redfield RR, Birx DL. Humoral responses to linear epitopes on the HIV-1 envelope in seropositive volunteers after vaccine therapy with rgp160. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 10:13-26.
43. 43. Muesing MA, Smith DH, Cabradilla CD, Benton CV, Lasky LA, Capon DJ. Nucleic acid structure and expression of the human AIDS/lymphadenopathy retrovirus. Nature 1985; 313:450-8.
44. 44. Myers G, Rabson AB, Josephs SF, Smith TF, Wong-Staal F. Human retroviruses and AIDS. Los Alamos, NM: Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, 1987.
45. 45. O'Brien VVA, Grovit-Ferbas K, Namazi A, et al. Human immunodeficiency virus-type 1 replication can be increased in peripheral blood of seropositive patients after influenza vaccination. Blood 1995; 86:1082-9.
46. 46. Staprans SI, Hamilton BL, Follansbee SE, et al. Activation of virus replication after vaccination of HIV-1-infected individuals. J Exp Med 1995; 182:1727-37.
47. 47. Glesby MJ, Hoover DR, Farzadegan H, Margolick JB, Saah AJ. The effect of influenza vaccination on human immunodeficiency virus type 1 load: a randomized, double-blind, placebo-controlled study. J Infect Dis 1996; 174:1332-6.
48. 48. Levi M, Ruden U, Birx D, et al. Effects of adjuvants and multiple antigen peptides on humoral and cellular immune responses to gp160 of HIV-1. J Acquir Immune Defic Syndr 1993; 6:855-64.
49. 49. Lowell GH, Kaminski RW, Van Cott TC, et al. Proteosomes, emulsomes, and cholera toxin B improve nasal immunogenicity of human immunodeficiency virus gp160 in mice: induction of serum, intestinal, vaginal, and lung IgA and IgG. J Infect Dis 1997; 175:292-301.
50. 50. Van Cott TC, Mascola JR, Kaminski RW, et al. Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160. J Virol 1997;71:4319-30.
51. 51. Loomis-Price LD, Cox JH, Mascola JR, et al. Correlation between humoral responses to human immunodeficiency virus type 1 envelope and disease progression in early-stage infection. J Infect Dis 1998; 178:1306-16.